Scheduling of fluorouracil: A forget-me-not in the jungle of doublets

Journal of Clinical Oncology

Volumn 22, Issue 1, 2004, Pages 4-6

  Sobrero, Alberto F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; HUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; TUMOR GROWTH;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 6344265942     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.974     Document Type: Editorial

References (18)

1. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
2. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
3. Hurwitz H. Fehrenbacher L, Cartwright T, et al: Bevacizumab prolongs survival in first line colorectal patients: Results of a phase III trial of bevacizumab in combination with bolus IFL as first line therapy in subjects with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:253, 2003 (abstr 1013)
4. Douillard JY, Cunningham D, Roth AD: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomised trial. Lancet 15:1372-1379, 2000
5. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment of advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
6. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusional/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21:129, 2002 (abstr 512)
7. Koehne CH, Van Cutsem E, Wils J: Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI group study 40986. Proc Am Soc Clin Oncol 22:254, 2003 (abstr 1018)
8. Maughan TS, James RD, Kerr DJ: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 36:457-564, 2003
9. Falcone A, et al: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil and leucovorin: A pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20:4006-4014, 2002
10. Rothenberg ML, Meropol NJ, Poplin E: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
11. Hochster H, Chachoua A, Speyer J, et al: Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 21:2703-2707, 2003
12. Ravaioli A, Marangolo M, Pasquini E, et al: Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 20:2545-2550, 2003
13. Van Cutsem E, Twelves C, Tabernero J, et al: XELOX: Mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective 1st line option for patients with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 22:1023, 2003
14. Patt YZ, Lin E, Leibman J. et al: Capecitabine plus irinotecan for chemotherapy naive patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:281, 2003 (abstr 1130)
15. Grothey A, Jordan K, Keliner O, et al: Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first line therapy of metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:255, 2003 (abstr 1022)
16. Colucci G, Maiello E, Gebbia V, et al: Preliminary results of a randomized multicenter study of the Gruppo Oncologico Italia Meridionale, comparing FOLFIRI vs FOLFOX in advanced colorectal cancer. Proc Am Soc Clin Oncol 22:255, 2003 (abstr 1021)
17. Tournigand C, Louvet C, Quinax E, et al: Folinic acid, fluorouracil, and irinotecan followed by folinic acid, fluorouracil, and oxaliplatin or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:10.1200/JCO.2004.05.113
18. De Gramont A, Banzi M, Navarro M, et al: Oxaliplatin/FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc Am Soc Clin Oncol 22:253, 2003 (abstr 1015)